David Hodl, Head of Business Development at Invetech, joined us to discuss the future of cell therapy manufacturing, ahead of Invetech’s appearance at Phacilitate’s Advanced Therapies Europe, Aug 31st –Sept 1st, and Invetech’s Michelle Duquette’s presentation of clinical data of its newly launched Korus platform, at the event (Sep 1st, 1:30 pm).
In this short interview, David Hodl describes the different solutions and systems being adopted in order to optimize cell-based therapy manufacturing and take development from the lab to a commercial scale.
Cell therapy manufacturers face many challenges when looking to streamline and scale processes in a safe, efficacious, and cost-effective manner. David notes that tackling these challenges involves, considering the variability of incoming starting materials, facing issues surrounding affordability and patient accessibility, and, recognizing the importance of standardization.
You can join Invetech’s Michelle Duquette at Advanced Therapies Europe in the session ‘THE CONTINUED RISE & APPLICATION OF AUTOLOGOUS THERAPIES’, Thursday the 1st of August at 1:30 pm, to hear more about Korus.
Find out more about Invetech’s Korus Technology here.
This interview has been produced in partnership with Invetech.
The contract and research organization (CRO) AmplifyBio has announced the acquisition of select assets from privately held biopharmaceutical company PACT Pharma Inc to advance its cell and gene therapy service offerings.
For this Article, Phacilitate Editor, Georgi Makin, explores current challenges associated with CAR-T manufacturing workflows, considering how an integrated testing approach could reduce costs and accelerate speed to market.